ABSTRACT
Primary pulmonary histiocytic sarcoma (PHS) has been reported, but is not well characterized. The aim of this retrospective study was to describe clinical characteristics, characterize prognostic factors and report the outcome of a larger group of dogs with primary PHS. Medical records of dogs diagnosed with primary PHS at 11 institutions were retrospectively reviewed. Thirty-seven dogs were included; 13 received CCNU-based chemotherapy alone, 18 received surgery and adjuvant CCNU-based chemotherapy, 3 received medical management alone and 3 dogs received surgery alone. The overall median progression free survival (PFS) and the median survival (overall survival [OS]) were 197 and 237 days, respectively. Measurable responses were noted in dogs receiving only chemotherapy; however, responses were not durable with PFS (91 days) and OS times (131 days) shorter than overall medians. Dogs that received surgery and chemotherapy had significantly prolonged PFS (276 days, P = 0.001) and OS (374 days, P = 0.001), compared with dogs not receiving surgery. As only three dogs undergoing surgery did not receive chemotherapy, it is not possible to determine the contribution of chemotherapy as an adjuvant to surgery. Dogs without evidence of intra-thoracic metastatic disease were much more likely to undergo surgery (odds ratio = 7.04; P = 0.018). While the presence of metastasis or clinical signs at diagnosis negatively impacted PFS, only the former negatively impacted OS. These data imply that dogs presenting with PHS amenable to surgery (ie, no clinical evidence of metastasis) benefit from surgical intervention; however, the lack of a comparable surgery alone group precludes assessment of the efficacy of post-surgical adjuvant chemotherapy.
Subject(s)
Dog Diseases/pathology , Histiocytic Sarcoma/veterinary , Lung Neoplasms/veterinary , Animals , Antineoplastic Agents/therapeutic use , Disease-Free Survival , Dog Diseases/diagnosis , Dog Diseases/drug therapy , Dog Diseases/surgery , Dogs , Female , Histiocytic Sarcoma/diagnosis , Histiocytic Sarcoma/pathology , Histiocytic Sarcoma/therapy , Lung Neoplasms/diagnosis , Lung Neoplasms/pathology , Lung Neoplasms/therapy , Male , Retrospective Studies , Survival AnalysisABSTRACT
The aim of this study was to determine whether or not canine lymphoma could be associated with a clinically relevant type B hyperlactatemia (> 2.5 mmol/L). The medical database from the University of Montreal Veterinary Medical Teaching Hospital was searched for confirmed cases of canine lymphoma with a blood lactate measurement. Information retrieved included stage, clinical observations compatible with causes of type A and B hyperlactatemia other than cancer, hepatic involvement, and drugs administered. Twenty (40%) dogs were hyperlactatemic. Five dogs (10%) were classified as having cancer-related hyperlactatemia. Seventy-five percent of hyperlactatemic dogs had clinical evidence of type A hyperlactatemia. In addition to lymphoma, 70% of hyperlactatemic dogs had evidence of an additional cause of type B hyperlactatemia. A significant association (P = 0.01) was identified between corticosteroid administration and hyperlactatemia. Cytological, echographic, and/or biochemical tests revealed hepatic changes in all hyperlactatemic dogs. Lymphoma alone may not be sufficient to explain clinically relevant hyperlactatemia in dogs.
